ficile coli
GASTROENTEROLOGY ARTICLE OF THE WEEK
May 31, 2007
Keeffe EB, Marcellin P. New and emerging treatment of chronic hepatitis B
1. Compared to lamivudine, Peginterferon achieves:
a. a higher rate of e-antigen seroconversion
b. a higher rate of s-antigen seroconversion
c. lower side effects
d. a better response particularly among those with elevated ALT levels
True or False
2. The dose of entecavir used in lamivudine resistant patients is twice that of the recommended dose for naïve patients
3. Combination therapy with Peginterferon and lamivudine results in a greater reduction of viral load during treatment but no difference in outcome 6 months after completing therapy.
4. Entecavir is active against HBV as well as HIV
5. Tenofovir has excellent activity against lamivudine resistant HBV
6. Entecavir inhibits HBV replication by binding to the HBV protease
7. Telvibudine is a good choice for treating lamivudine resistant-HBV
8. Entecavir resistance has not been demonstrated in naïve patients treated for up to 2 years, among lamivudine resistant patients, entecavir resistance is seein in 9% at 2 years
9. Emtricitabine has cross-resistance with lamivudine
10. Telbivudine has strong anti-HBV activity, but a 4.5% resistance rate at year 1